- 1 Prediction of the risk for diabetic neuropathy among diabetes mellitus patients at
- 2 selected referral hospitals, in Amhara regional state Northwest Ethiopia, January,
- 3 2005- December 2021; Development and validation of risk prediction model
- 4 Negalgn Byadgie Gelaw*1* Achenef Asmamaw Muche² Adugnaw Zeleke Alem³ Nebiyu
- 5 Bekele Gebi⁴ Yazachew Moges Chekol⁵ Tigabu Kidie Tesfie⁶ Tsion Mulat Tebeje⁷
- 6 ¹Department of public health, Mizan- Aman College of health sciences, Mizan- Aman,
- 7 Ethiopia
- 8 ²Department of Epidemiology and biostatics, College of medicine and health sciences,
- 9 University of Gondar, Gondar, Ethiopia
- ³Department of Epidemiology and biostatics, College of medicine and health sciences,
- 11 University of Gondar, Gondar, Ethiopia
- ⁴Department of internal medicine, School of Medicine, University of Gondar comprehensive
- specialized hospital, Gondar, Ethiopia
- ⁵Department of Health Information Technology, Mizan Aman College of health sciences,
- 15 Mizan-Aman, Ethiopia
- ⁶ Department of Public Health, College of Health Sciences, Debre Markos University, Debre
- 17 Markos, Ethiopia
- ⁷ Unit of Epidemiology and biostatistics, School of public health, college of medicine and
- 19 health sciences, Dilla University, Dilla, Ethiopia
- 20 Corresponding Author *1* (negalgnbyadgie21@gmail.com)
- 21 Emails:
- NBG; negalgnbvadgie21@gmail.com
- 23 AAM; ashua2014@gmail.com
- 24 AZA: aduzeleke2201@gmail.com
- 25 NBG; dawabekele@gmail.com

26 YMC; yazachewmoges@gmail.com

TKT: tigabukidie@gmail.com

TMT; yemarina12@gmail.com

Abstract

27

28

29

30

38

39

41

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

Background:-Diabetic neuropathy is the most common complication in both Type-1 and 31 32 Type-2 DM patients with more than one half of all patients developing nerve dysfunction in 33 their lifetime. Although, risk prediction model was developed for diabetic neuropathy in 34 developed countries, It is not applicable in clinical practice, due to poor data, methodological problems, inappropriately analyzed and reported. To date, no risk prediction model 35 36 developed for diabetic neuropathy among DM in Ethiopia. Therefore, this study aimed 37

prediction the risk of diabetic neuropathy among DM patients, used for guiding in clinical

decision making for clinicians

40 **Objective:-** Prediction of the risk for diabetic neuropathy among diabetes mellitus patients.

in selected referral hospitals, Amhara regional state, northwest Ethiopia, 2022

42 Methods:- A retrospective follow up study was conducted with a total of 808 DM patients

were enrolled from January 1,2005 to December 30,2021 at two selected referral hospitals in

Amhara regional state. Multi-stage sampling techniques were used and the data was collected

by checklist from medical records by Kobo collect and exported to STATA version-17 for

analysis. Lasso method were used to select predictors and entered to multivariable logistic

regression with P-value<0.05 was used for nomogram development. Model performance was

assessed by AUC and calibration plot. Internal validation was done through bootstrapping

method and decision curve analysis was performed to evaluate net benefit of model

Results:-The incidence proportion of diabetic neuropathy among DM patients was 21.29 %(

95% CI; 18.59, 24.25). In multivariable logistic regression glycemic control, other

comorbidities, physical activity, hypertension, alcohol drinking, type of treatment, white

blood cells and red blood cells count were statistically significant. Nomogram was

developed, has discriminating power AUC; 73.2 %(95% CI; 69.0%, 77.3%) and calibration

test (P-value = 0.45). It was internally validated by bootstrapping method with discrimination

performance 71.7(95% CI; 67.2 %, 75.9%). It had less optimism coefficient (0.015). To make

nomogram accessible, mobile based tool were developed. In machine learning, classification and regression tree has discriminating performance of 70.2 %(95 % CI; 65.8%, 74.6%). The model had high net benefit at different threshold probabilities in both nomogram and classification and regression tree.

Conclusion:- The developed nomogram and decision tree, has good level of accuracy and well calibration, easily individualized prediction of diabetic neuropathy. Both models had added net benefit in clinical practice and to be clinically applicable mobile based tool were developed.

Key-words:-Prediction, Diabetes mellitus, Diabetic neuropathy, Ethiopia

Background

68

- 69 Diabetes mellitus is metabolic disorder disease characterized by increasing blood glucose
- level in the body resulting from either defect insulin secretion, insulin action, or both(1) with
- around 90% have type 2 DM and 10% have type-1 DM(2). According to IDF, the global
- prevalence of diabetes mellitus in 20-79 year olds at 2021 was estimated to be 536.6 million
- people, rising to 783.2 million in 2045(3).
- Globally, around 3 million deaths annually is due to DM and 49.7% living with diabetes
- undiagnosed (4). It is one of the most common problem in the world has faced both in
- developed and developing countries (5). In Africa, by 2019, around 19 million adult
- populations were estimated to have diabetes and it is expected that by 2045 it will be around
- 47 million and similarly in Ethiopia, an estimated 1,699,400 adults were living with diabetes
- 79 mellitus(6).
- 80 The chronic hyperglycemia of diabetes mellitus had long-term damage, dysfunction, and
- 81 failure of different organs such as nerves, eyes, kidneys(7). Diabetic neuropathy defined as
- 82 presence of symptoms and signs of peripheral nerve dysfunction in people with diabetes
- mellitus after exclusion of other causes(8). The mechanism of nerve dysfunctions was through
- 84 metabolic process by hyperglycemia due to oxidative stress, directly affecting nerve fibers
- 85 (9). It is the most common complication of both type-1 and type-2 DM with more than one
- 86 half of all patients developing nerve dysfunction in their lifetime (10).
- 87 The Burdon of diabetic neuropathy common in industrialized countries ranges from in china,
- 88 33.1%(11) to 40.3% among patients with type-1 diabetes mellitus and 42.2% with type-2
- diabetes mellitus in Germany (12). Evidence from previous study documented shows that in
- 90 Latin American and Caribbean countries, the incidence of diabetic neuropathy was 29.2%
- 91 (13) and in Sri Lankan 28.8%(14).
- 92 In Africa, according to a systematic review and meta-analysis done, the overall pooled
- prevalence of diabetic neuropathy was 46% (15). In south Africa 30.3% (16) ,in Ghana 8.1%
- 94 (17), in Northern Africa, incidence ranges from 21.9% to 60% (18).
- 95 In Ethiopia, the prevalence of diabetic neuropathy ranges from 16.63% at university of
- 96 Gondar comprehensive specialized referral hospital to 52.2% at Bahir-Dar city (19), at Tikur-
- Anbesa and St. Paul's specialized university hospital was 48.2% with 53.6% in type 2 and
- 98 33.3% in type 1 diabetes mellitus patients(20).
- 99 As part of NCD prevention and treatment strategies, diabetic neuropathy and related
- complications are getting attention at the national and international levels(21). Guidelines are
- recommending that by multidisciplinary team approach can treating and preventing diabetic

102 neuropathy. WHO and other professional society guideline are also recommended that strengthening of the surveillance & management of diabetic neuropathy was important to 103 reduce the incidence and its consequence(22). 104 Despite different strategies and initiatives implemented to reduce the Burdon of diabetic 105 106 neuropathy, up to one third of patients with diabetes have neuropathic pain(23) which often 107 leads to sleep disturbance, poor quality of life, depression, and unemployment. Both acute and chronic diabetic neuropathies had occur in DM patients (24) that results diabetic foot 108 109 disease, including ulceration and non-traumatic amputations that might be due to lack of screening tool that can be used to identify diabetic patients who is at risk of diabetic 110 neuropathy. 111 Although, risk prediction model for diabetic neuropathy among DM patients in developed 112 countries was developed, it is not applicable in clinical practice due to poor data, 113 methodological problems, inappropriately analyzed and poorly reported(25). Delay and lack 114 of detection of the complication was mostly resulted from patients being asymptomatic 115 during the early stage of the disease(26). So that a simple and accurate risk prediction tool to 116 identify those at high risk of patents develop to diabetic neuropathy had great value. 117 Early identification of high risk DM patients using simple screening tool, avoids late 118 119 diagnosis of diabetic neuropathy that reduces huge economic costs and serious complications (27). Thus, a method used to provide information about their level of risk was 120 needed to take timely intervention measures to prevent occurrence of diabetic neuropathy. 121 Many epidemiological studies on diabetic neuropathy, including cross-sectional studies are 122 carried out around the world to explore the risk factors associated with diabetic neuropathy 123 (12, 28) but level of risk to develop diabetic neuropathy for DM patients was unknown. 124 Hence studies suggest that patient specific model like individual patients risk prediction 125 model is useful to alleviate the problem. 126 Risk prediction models have been used to predict the probability of risk of diseases used in 127 medicine and public health to guide clinical decision-making(29). However, risk prediction 128 model for diabetic neuropathy among DM patients have not been developed in Ethiopia. 129 There was variability in the clinical diagnosis of diabetic neuropathy in different setting 130 (30). Thus, this prediction model considers prognostic factors that have been generally 131 monitored in clinical practice and precisely measured to ensure its feasibility and accuracy 132 for clinical application. Currently an urgent change for improvement of the diagnosis and 133 134 management of diabetic neuropathy were needed(31).

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

According to a previous risk prediction model conducted to identify DM patients at risk of developing diabetic neuropathy being old age(32), sex(33), educational level (34) were significant predictors with area under ROC curve of 0.957. In another study, age(35), residence (3), BMI (36), educational level (34), poor diabetic control(37), type of DM(38), duration of diabetes mellitus (39), number of hypoglycemic drugs used (40) with AUC 0.859 were also determinates of diabetic neuropathy. Hemoglobin level(41), presence of other micro and macro vascular complications(13), hypertension(39), type of DM (33) baseline comorbidities(42), complications such as diabetic nephropathy, diabetic-retinopathy(12), lipid profile(triglyceride, cholesterol)levels (43), fasting blood glucose (44, 45), HbA1c (46), high level of alcohol drinking(13) physical inactive(39), eating fat containing foods(47) were the most common predictors of diabetic neuropathy. Although, different strategies and interventions have been made so far, to reduce the Burdon diabetic neuropathy, Overtime at least 50% of individuals with diabetes develop diabetic neuropathy(48). It is preventable through detected early the high risk patients, by providing timely intervention measures. However, identifying high risk patients for diabetic neuropathy was not performed as expected(26). Until an advanced stage, diabetic neuropathy is asymptomatic but it can be prevented through identifying high risk patients and prompt treatment before their complication. Up to my knowledge there is no risk prediction model for diabetic neuropathy among DM patients in Ethiopia. As a result, this risk prediction models alleviate the problem by developing nomogram and decision tree, estimate disease risk, can guide healthcare providers for disease intervention and arrangement future health care needs by providing treatment. Monitoring biomarkers and other predictors is also very essential to be aware of metabolic abnormality by providing meaningful prognostic information that can help to differentiate patients with regard complication and lead the way to change other intervention. This risk prediction model was developed by applying sound statistical methods and analysis to identify DM patients at which level of risk for the development of diabetic neuropathy (49). Besides, the finding of this study was highly useful as a simple clinical tool to guide clinicians for decision making, aid for specific screening of high-risk patients and for their informed choice of treatment to the patients. Therefore, these studies aimed development and validation of risk prediction model for diabetic neuropathy among diabetes mellitus patients in selected referral hospitals at Amhara regional state, Ethiopia.

Methods and materials

Study design and area

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

mellitus was excluded

An institution-based retrospective follow up study was conducted among patients diagnosed with diabetes mellitus from January 1, 2005 to December 30, 2021. The study area was selected referral hospitals in northwest part of Amara regional state, which includes University of Gondar Comprehensive specialized and referral hospital, Debre markos comprehensive specialized hospital, Tibebe-Gihon comprehensive specialized referral hospital, Felge-Hiwot comprehensive specialized referral hospital, and Debre tabor comprehensive specialized referral hospital. Using lottery Method, University of Gondar comprehensive specialized referral hospital and Felege-Hiwot comprehensive specialized referral hospital was selected. University of Gondar comprehensive specialized hospital found in Gondar town, far from Addis Abeba, the capital city of Ethiopia 750 km and 200 km from Bahir-dar, the capital city of Amhara regional state. It serves for more than 7 million people in northwest Ethiopia. The hospital serves around 24,862 numbers of people are having chronic follow-up per year, and among this, 4760 were DM patients. Felege-Hiwot Referral Hospital is found in Bahir-Dar, which is the capital city of Amhara regional state located at 565 km from Addis Ababa, Northwest Ethiopia. It serves as over 7 million people from the surrounding area. Around 21,218 people had a chronic follow-up in this hospital and among these 4200 were DM patients. The study setting was displayed below **Population** The source population was all people diagnosed with diabetes mellitus having a follow up at selected referral hospitals in Amhara regional state, North West Ethiopia and all people having confirmed diabetes mellitus started treatment and follow up at selected referral hospitals in Amhara regional state with in follow up period were study population. A diabetes mellitus patient who was enrolled from January 1, 2005 to December 30, 2021 with minimum of two years follow up, at university of Gondar comprehensive specialized hospital and Felege-Hiwot comprehensive specialized referral hospital were included. Diabetes mellitus patients whose date of initiation was not recorded and incomplete charts, those DM patients develop diabetic neuropathy at beginning, transferred in and gestational diabetes

Sample size calculation and sampling technique

- 200 In risk prediction model development sample size was calculated through different
- approaches/methods either considering Minimum Mean Absolute Prediction Error (MAPE) 201
- to be minimum and use shrinkage factor to be minimize the issue of over fitted model. 202
- Therefore, by applying the expected average error of predicting the outcome when the 203
- developed prediction model is going to be applied to new individuals should be considered, 204
- that is called Mean Absolute Prediction Error (MAPE) should be minimum. Sample size also 205
- can be calculated using the following formula by taking the prevalence according to a 206
- systematic review and meta-analysis study done in Ethiopia, the prevalence of diabetic 207
- neuropathy among diabetes mellitus patients was 22%(50). 208

- 210
- Here ϕ -is the proportion of diabetic neuropathy P- is the number of predictors used to 211
- predict the diabetic neuropathy and MAPE is the mean absolute prediction error of maximum 212
- 213 5% considered in our case.

199

214
$$n = \exp\left(\frac{-0.508 + 0.259 \ln(0.22) + 0.504 \ln(22) - \ln(0.05)}{0.544}\right) = 475$$

- The second method is taking the issue of over fitted model in to consideration in prediction 215
- model. We have targeted less than 10% over fitted model for predicting diabetic neuropathy 216
- in DM patients. The amount of sample size required to minimize the problem of over fitting 217
- should be identified. We consider the following sample size formula. 218

219
$$n = \frac{P}{(S-1)\ln\left(1 - \frac{R_{CS}^2}{S}\right)}$$
 Equation 2

221
$$\max (R_{CS}^2) = 1 - \exp\left(\frac{2\ln L_{\text{null}}}{n}\right)$$
.....Equation 2b

224
$$\ln \text{Lnull} = 22\ln\left(\frac{22}{100}\right) + (100 - 22)\ln\left(1 - \frac{22}{100}\right) = -52.7$$

225
$$\max (R_{CS}^2) = 1 - \exp(\frac{2*-52.7}{100}) = 0.65$$

223

226
$$R_{CS}^2 = R_{nagelkerke}^2 * max (R_{CS}^2) = 0.5*0.65 = 0.325$$

227
$$n = \frac{P}{(S-1)\ln(1-\frac{R_{CS}^2}{S})} = \frac{22}{(0.9-1)\ln(1-\frac{0.325}{0.9})} = 492$$

- Here, *inLnull* is the log-likelihood of an intercept-only model; E is the total numbers of DM
- patients develop diabetic neuropathy, S- shrinkage factor taken as 0.9 for optimum non-over
- 230 fitted model n- is the arbitrary sample size from it E occurs. Max R²CS is the maximum cox-
- Snell variability explained by the model δ is the expected model optimism, $R_{nagelkerke}^2$ is
- also a fundamental overall measure of model fitness, it is usually considered as default of 0.5.
- From the above different types of approaches for sample size calculation in risk prediction
- model the largest sample size is 492 and since multi stage sampling technique was used,
- design effect taken as equal to 1.5, Then 492*1.5=738 Finally by adding 15% contingency
- because of while during data extraction checklist pretesting, to check completeness and
- clarity of checklist, most of the patient medical record number was absent in the medical
- record room by taking in to consideration such missing charts, adding 10-15% contingency
- was recommended so, the total minimum sample size was 849.
- Multi stage sampling techniques were used by first selecting the referral hospitals in North
- West part of Amhara regional state. Among these referral hospitals by using lottery method
- 242 UOG comprehensive specialized referral hospital and Felege-Hiwot comprehensive
- specialized referral hospital were selected. Then, study participates were selected by first
- proportion allocation to each selected referral hospitals through the following proportional
- 245 allocation formula.
- 246 $ni = \frac{n}{N} * Ni$ Where n=Total sample size N-total population ni- sample size for each hospital
- 247 Finally the study participates was selected by using computer random generated number
- 248 through preparing sampling frame by arranging his/her medical record number order.
- A total of 8960 Type-1 and Type-2 diabetes mellitus patients were enrolled from January 1,
- 250 2005 up to December 30,2021 and had follow up at university of Gondar comprehensive
- 251 specialized referral hospital and Felege Hiwot comprehensive specialized referral hospital.
- 252 The flow chart of participates selection was displayed (Figure-1).
- 253 Figure 1:-Flowchart of participant selection for the development of nomogram for
- prediction of diabetic neuropathy among DM patients in selected referral hospitals,
- Amhara regional state, North West Ethiopia, 2005-2021.

Variables

256

257

Dependent variable

- 258 Diabetic neuropathy
- 259 Independent variable
- Socio demographic variables: Baseline age (year), sex, residence, body mass index
- 261 Laboratory related variables: Mean fasting blood glucose level, Mean arterial blood
- pressure, baseline total cholesterol, baseline triglyceride level, baseline value of WBC, RBC,
- platelets count, baseline hemoglobin and creatinine level
- 264 Diagnosis and treatment related variables; Type of DM, duration of DM, Type of
- treatment for DM, hypertension, baseline other comorbidities and adherence
- **Behavioral related variables;** Alcohol drinking, unhealthy diet, physical activity
- **Operational definition**
- Diabetic neuropathy; It can be either small fiber neuropathy or large fiber neuropathy.
- Small fiber neuropathy manifested by pain, tingling, paraesthesia and confirmed by pinprick
- and temperature examination. Large fiber neuropathy is manifested by numb feet and gait
- 271 ataxia and confirmed by touch sensation by 10g monofilament, vibration sense by
- biothesiometer and ankle reflex. A patient is considered as having diabetic neuropathy if
- 273 he/she is diagnosed as diabetic neuropathy on his/her medical record (51).
- Other comorbidities; if other baseline disease (except hypertension) in DM patients were
- present such as ischemic heart diseases, stroke, e.t.c
- Mean arterial blood pressure; calculated as MABP = (SBP + (2 * DBP))/3
- 277 Normal----- 70-100 mmHg
- 278 ➤ High----->100mm Hg
- 279 **Glycemic control**: Patients was classified as per the WHO criteria into:
- ≥ Good glycemic control = fasting blood glucose of 80–130 mg/dl
- Poor glycemic control = fasting blood glucose of > 130 mg/dl----- (52)
- 282 Total cholesterol:

Total Triglyceride

- Normal = <200 mg/dl Normal = <150 mg/dl
- ≥ High -- >200 mg/dl ----(53) High----->150mg/dl ----(53)
- 285 White blood cells Red blood cells

Normal---- 4,500-11,000 cells/micro liter Normal= 4-6 million cells/ml

 \triangleright Low ----- <4,500 cells/ml Low =<4 million cells/ml

288 > High ---- >11,000 cells/ml--(54) High >6 million cells/ml---(54)

Platelets

Body mass index:

290 Normal ----150,000-400,000 cells/ml Underweight =
$$BMI < 18.5 \text{ kg/m}^2$$

292 High --
$$>400,000 \text{ cells/ml}$$
-----(54) Overweight = BMI $>=25 \text{ kg/m}^2$ -- (55)

Data collection tools and quality control

This risk prediction model was used secondary data source, collected from June 8 to July 10, 2022 using the developed data extraction check lists. The reviewed records were identified by their medical registration number. Patient intake form, follow-up card, and DM registration book were used as data sources. Socio-demographic characteristics, behavioral characteristics, baseline, and follow-up clinical and laboratory data were collected from patient cards. The date that patients start regular follow-up treatment until the end of the study to the confirmation of a final event in the study period was collected. Four trained BSc nursing health professional and two public health officer supervisors were recruited for data collection. Training on the objective of the study and how to retrieve records as per data extraction checklists were given to data collectors and supervisors one day before data collection. As well as, random sample from data extracted was crosschecked for its consistency. The information formats were crosschecked with the source card on the spot, and regular supervisions were done.

Data processing and analysis

Data was coded and entered to Kobo collect Version v2022.1.2 for clean-up and then exported to Stata version-17 for analysis. Descriptive statistics (frequency, percentage, proportion, and mean with standard deviation, median with IQR) were used to describe the clinical course of diabetic neuropathy diseases. The candidate prognostic factors were selected by using the least absolute shrinkage and selection operator (LASSO) method, by shrinking variables with very unstable estimates towards zero, it can effectively exclude some irrelevant variables and produce sparse estimations while variables with nonzero

regression coefficient was considered as most strongly associated with the response variable.

Then selected variables by (LASSO) method were entered in to multivariable logistic

regression and model reduction was done using log likelihood ratio test >0.15 and finally p-

value < 0.05 in model reduction were taken as statistically significant predictors and beta

coefficients with 95% CI was reported. Mullti-collinerity was checked by variance inflation

factor where VIF > 10 indicate the presence of multi-collinearity.

Missing data management

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

336

337

338

339

343

345

Missing variable with value <50%, the missing data was handled by multiple imputation

through checking the type of missing data. In this risk prediction model the missing variable

was checked by fitting statistical test (logistic regression) found a result, the missing variable

was associated with the observed variables, indicates that Missing at random (MAR). The

percentage of missing value was done by "mdesc" package by STATA version-17 and if the

missing value >= 50%, were not included in our model. From 22 predictors, six of them had

complete data: baseline age, sex, residence, type of DM, type of treatment for DM and

duration. The remaining missing variables were managed by multiple imputation technique,

better that considers mean and variance and decreases uncertainty or bias. The missing

variables and its percentage value was found in (Supplementary file S-1)

Risk prediction model development

- In risk prediction model development both the prognostic markers and determinates that
- predict the diabetic neuropathy was selected from socio-demographic factors, diagnosis and

335 treatment related factors, laboratory related factors and behavioral related factors. The

determinants factors included in the multivariable logistic regression analysis were selected

based on the results of lasso regression method. The theoretical design was the incidence of

diabetic neuropathy at a future time "t" is a function of prognostic determinants ascertained

- at one time (baseline) points before the occurrence of the diabetic neuropathy ("t0")
- The occurrence relation was incidence of DN = f (Comorbidities, glycemic control, alcohol
- 341 drinking+ physical activity + hypertension+ type of treatment+ WBC count+ RBC count)
- Domain: All type-1 and type-2 DM patients at risk for developing diabetic neuropathy

Nomogram and classification and regression tree development

Nomogram, which are reliable prediction tools, with the ability to generate an individual

probability of a clinical event by incorporating a number of prognostic determinant variables

(56) was developed to predict individual risk of diabetic neuropathy among DM patients at diabetic clinic of university of Gondar comprehensive specialized hospital and Felege Hiwot referral hospital. The total nomogram score were classified as low risk, intermediate and high-risk scores to see size of each category. Classification and Regression Tree (CRT) analysis was performed to determine the complex interactions among the most potent candidate predictors in the final reduced model to build the classification trees. Youden-index was used to estimate cut off point for predictive probability of diabetic neuropathy at different threshold. By choosing the cutoff value get from Youden's index the sensitivity, specificity, NPV, PPV and accuracy was calculated and cut off value was selected depend availability of resources and aim of implemented program.

Risk prediction model performance

- The reduced multivariable model was evaluated by calibration and discrimination (57).
- Model discrimination is the model's ability to discriminate between subjects with and without the diabetic neuropathy was estimated through the areas under the ROC curve. The
- area under the receiver operating characteristic curve (AUC) ranges between 0.5-1. Model
- calibration is examined the level of agreement between the diabetic neuropathy probabilities
- 362 estimated by the model versus the observed diabetic neuropathy frequencies through
- 363 graphical comparison, calibration plot. Good calibration means that the estimated probability
- of diabetic neuropathy is similar to the observed diabetic neuropathy frequency. Statistically
- we checked by the Homer and Lemeshow test with a significant P- value implies that the
- model is not well calibrated as it performs differently for different risk categories. Finally the
- results were presented using statement, table, figures and reported according to transparent
- 368 reporting of multivariable prediction model for individual progress or diagnosis
- 369 (TRPOID)statement(58)

346

347

348

349

350

351

352

353

354

355

356

357

370

Internal validation

- 371 In risk prediction model, validating the model expected from the researchers in order to apply
- in clinical practice. In this study by using bootstrapping method internal validation was done
- to avoid over fitting of the model (57). The first step in bootstrapping method is the model
- was developed in the full sample. Then multiple random minimum samples (1000) draw
- 375 from the full sample. The calibration and discrimination of each bootstrap model were
- 376 compared to the corresponding estimates of the bootstrap models when applied in the

original full sample. These differences were averaged, and provide an indication of the average optimism of the bootstrap models.

Decision curve analysis

Decision curve analysis was done to evaluate prediction models that is important for medical decision making to overcome the limitations discrimination and calibration(59). It was done graphically for model, treatment for all, and treatment for none. The net benefit of the developed model for carrying out a certain intervention measure in DM patients at risk of developing diabetic neuropathy was done by decision curve plot.

Mobile based application of Nomogram

Application of the nomogram by mobile based is useful to facilitate limited resources in poor healthcare systems to get evidence based clinical decision making. To make the nomogram accessible to physicians and patients, mobile based application tool were developed for predicting risk of diabetic neuropathy in diabetes mellitus patients. The mobile based tool was developed by "sublime text" application with java script and used to calculate the risk of diabetic neuropathy for DM patients without requiring internet service "off line" in clinical setting. Where clinicians or diabetes mellitus patients enter his/her selected clinical and laboratory data then developed mobile based application toll giving alert as low risk or high risks of diabetic neuropathy to keep or improve their health condition.

Results

Socio-demographic and behavioral characteristics of DM patients

A total of 808 diabetes mellitus patients who had follow up visit were included. The mean baseline age of diabetes mellitus patients was 45.6±3.1 years. More than three-fourth 616(76.2%) diabetes mellitus patients were from urban residents (Table-1)

Table 1:-Socio-demographic and behavioral predictors of diabetic neuropathy among diabetes mellitus patients in North West, Ethiopia, 2005-2021 (n=808)

Predictors	Diabetic Neuropathy		Frequency	Percentage
	Yes	No	_	
Sex				
Male	73	327	400	49.5

Female	99	309	408	50.5
Baseline age				
< 45 years	62	321	383	47.4
>=45 years	110	315	425	52.6
Residence				
Rural	26	166	192	23.8
Urban	146	470	616	76.2
Alcohol drinking				
Yes	74	98	172	21.3
No	287	349	636	78.7
Physical activity				
Yes	311	325	636	78.7
No	75	97	172	21.3
Unhealthy diet				
Yes	83	89	172	21.3
No	321	315	636	78.7

Diagnosis and treatment related characteristics of DM patients

More than two-third of patients 545(67.5%) were type-2 DM patients and half of them 401(49.6%) diabetes mellitus patients were used oral drugs medication. Nearly half of the diabetes mellitus patients 385(47.6%) had other comorbidities. Majority of diabetes mellitus patients 557(71.4%) had good adherence (Table-2).

Table 2:-Clinical predictors of diabetic neuropathy among diabetes mellitus patients North West, Ethiopia, 2005-2021 (n=808)

Predictors	Diabetic Neuropathy		Frequency	Percentage			
	Yes	No					
Type of diabetes mellitus							
Type-1 DM	35	228	263	32.5			
Type-2 DM	137	408	545	67.5			
Type of treatment for diabe	etes mellitus						
Insulin only	55	293	348	43.1			
Oral drugs only	96	305	401	49.6			

Insulin and oral drugs	21	38	59	7.3			
Body mass index in kg/m ²							
<18.5	9	28	37	4.6			
18.5-24.9	54	191	245	30.3			
>=25	109	417	526	65.1			
Mean arterial blood pressure							
>100 mmHg	62	152	214	26.5			
70-100 mmHg	110	484	594	73.5			
Other comorbidities							
Yes	50	373	423	52.4			
No	122	263	385	47.6			
Adherence							
Poor	52	179	231	28.6			
Good	120	457	577	71.4			
Hypertension							
Yes	99	244	343	42.5			
No	73	392	465	57.5			
Duration of DM in years							
<6 years	71	257	328	40.6			
6-11 years	79	316	395	48.9			
>11 years	22	63	85	10.5			

Laboratory related characteristics of diabetes mellitus patients

The mean value of fasting blood glucose level was 92 ± 15 and the mean total cholesterol and total triglyceride level had 189.9 ± 58.7 and 170.5 ± 73.7 mg/dl respectively. (Table-3)

Table 3:-Laboratory related predictors diabetic neuropathy among diabetes mellitus patients North West, Ethiopia, 2005-2021(n=808)

Predictor	Mean \pm SD
Mean fasting blood glucose(mg/dl)	92 ± 15
Hemoglobin(g/dl)	13.9 ± 1.8
Total cholesterol level(mg/dl)	189.9 ± 58.7

Total triglyceride level(mg/dl)	170.5 ± 73.7
Creatinine(mg/dl)	0.9 ± 0.6
White blood cells(Cells/microliter)	$6.9 \pm 2.8 \text{ x} 10^3 \text{ cells/mcl}$
Red blood cells(Cells/microliter)	$4.8 \pm 0.9 \text{x} 10^6 \text{ cells/mcl}$
Platelets(Cells/microliter)	$233 \pm 74 \times 10^3 \text{ cells/mcl}$

Incidence of diabetic neuropathy

- The incidence proportion of diabetic neuropathy was 172 (21.29 %, 95% CI; 18.59, 24.25) 418
- 419 Type-2 diabetes mellitus 137(79.65%) had highest incidence of diabetic neuropathy whereas
- 35(20.35%) were found in type-1 diabetes mellitus patients. (Figure-2) 420
- 421 Figure 2; Pie chart for the proportion of diabetic neuropathy among diabetes mellitus
- patients North West, Ethiopia, 2005-2021. 422

Prediction model development and validation 423

Selected predictors

- In this risk prediction model socio-demographic, diagnosis and treatment related, laboratory 425
- 426 and behavioral related predictors were considered for development of prediction model of
- diabetic neuropathy. 427

417

424

432

433

434

- The candidate predictors were selected by least absolute shrinkage and selection operator 428
- (LASSO) regression for the development and validation of model for diabetic neuropathy 429
- 430 (Table-4). Multi- collinerity test was checked by VIF and unhealthy diet was not included in
- our model due to high VIF (17.8). 431

Table 4:- Optimum shrinkage factor (lambda) and potential predictors identified by lasso regression by 10-fold cross validation selection method for diabetic neuropathy among diabetes mellitus patients North west, Ethiopia 2005-2021.(n=808)

ID	Description	Lambda	No. of non- zero	Out of sample	CV
			coefficients	dev. Ratio	devianc
1	First lambda	0.09923	0	0.0023	1.03789

			coefficients	dev. Ratio	deviance
1	First lambda	0.09923	0	0.0023	1.037898
21	Lambda before	0.015437	12	0.0575	0.9759118
*22	selected lambda	0.0140656	13	0.0578	0.0756381
23	Lambda after	0.012816	13	0.0576	0.9757846
27	Last lambda	0.0088336	19	0.0553	0.9782416

mean

Thirteen variables were selected by Lasso regression and included in the multiple logistic regression models (Table-5). Finally, we construct the clinical risk prediction model with eight statistically significant predictors including hypertension, glycemic control (FBG), other comorbidities, Alcohol drinking, physical activity, type of treatment for DM, WBC and RBC count. Goodness of fit test was checked had insignificant p-value 0.3077, best fitted model.

Table 5:-Multi variable logistic regression for variables retained in the final reduced model to predict diabetic neuropathy among DM patients Northwest Ethiopia, 2005-2021. (n=808)

Predictors	Dial	petic	Multi variable anal	ysis	Model reduction	
	neuro	pathy				
	No	Yes	Beta coefficients	P-value	P- value	
			(95 % CI)			
Baseline age in ye	ears					
<45 years	321	62	0			
>=45 years	315	110	0.15(-0.28,0.59)	0.516		
Sex						
Female	309	99	0			
Male	327	73	-0.26(-0.63,0.10)	0.157		
Residence						
Rural	166	26	0			
Urban	470	146	0.28(-0.23,0.79)	0.279		
Type of DM						
Type-1 DM	228	35	0			
Type-2 DM	408	137	0.024(-0.6, 0.7)	0.944		
Mean arterial bloo	od press	sure				
70-100 mmHg	484	110	0			
>100 mmHg	152	62	0.15(-0.25,0.56)	0.459		
Type of treatment	t					
Both insulin and	38	21	0			
oral drug						
Insulin only	305	96	-0.49(-1.32,0.10)	0.05	0.02 *	

Oral drugs only	293	55	-0.61(-1.09,0.15)	0.139	
Baseline glycemi	c contro	1			
<130mg/dl	148	25	0		
>=130mg/dl	488	147	0.58(-0.01 ,1.16)	0.04	0.04*
Other comorbidit	ies				
No	373	50	0		
Yes	263	122	1.29(0.85,1.68)	0.000	0.00*
Alcohol drinking					
No	349	287	0		
Yes	98	74	1.13(.015, 2.25)	0.04	0.003*
Physical Activity					
No	97	75	0		
Yes	325	311	-1.79(-2.94,-0.7)	0.002	0.001*
Hypertension					
No	392	73	0		
Yes	244	99	0.412 (0.00, 0.82	0.04	0.01*
White blood cells	s/microli	ter			
4500-11000	266	82			
<4500	33	20	-1.14(-2.2, -0.01)	0.04	0.03*
>11000	337	70	0.15(-0.58, 0.89)	0.684	
Red blood cells/n	nicrolite	r			
4-6 million	270	80	0		
<4 million	34	20	0.90(.056 ,1.74)	0.03	0.03*
>6 million	332	72	-0.24(-0.99 0.52)	0.539	
_cons			-1.96(-2.97,0.94)	0.000	

Prediction model development using original beta coefficients

By using area under ROC curve the discriminating power of the model was evaluated and individual predictors in the final reduced model had poor performance discriminating the risk of diabetic neuropathy among DM patients starting from 51.1 % to 62 .4% but they had good discriminating ability in combined effect. The predictive performance of model using combination of other comorbidities, glycemic control, physical activity and WBC had 70.0%. The predictive performance powers of each predictor were displayed (supplementary file S-

- 2). The area under curve (AUC) of the final reduced model using original beta coefficients
- were 73.49 %(95% CI; 69.3%, 77.6%).(Figure-3, A). The developed model had calibration
- 455 test value (p-value=0.451) well calibrated model, the model well represented the data that
- was agreement between observed and the predicted probability (Figure-3, B)
- 457 Figure 3: The performance of the model using original beta coefficients A) AUC B)
- calibration plot, for prediction of diabetic neuropathy among DM patients North West
- 459 Ethiopia, 2005-2021.

- The probability for risk of diabetic neuropathy using original beta coefficients was
- 461 P(Diabetic-neuropathy)= $1/1+\exp(-1.96+0.9*RBC(low)-1.14*WBC(low)+0.4*Hypertension$
- 462 (yes)-1.79*Physical activity (yes) +1.13*Alcohol drinking (yes) +1.29*other comorbidities
- (yes) +0.58*Glycemic control (poor)-0.72*type of treatment (insulin only)

Prediction model development using nomogram

- 465 For the sake of simplicity and easy to use in clinical practice the model was developed by
- 466 nomogram (Logistic regression). All significant regression coefficients in the final reduced
- 467 model were used for model development. The model presented by monogram through eight
- significant variables that predicts diabetic neuropathy was displayed (Figure-4). From
- nomogram the possible minimum and maximum score was 0 to 47.2 with different threshold
- 470 probabilities to develop diabetic neuropathy. The cut off value to nomogram score as the
- 471 probability of 0.24 was 26. Hence, DM patients who had <26 score from nomogram total
- score was low risk whereas those who had >=26 score from total score was as high risk to
- 473 develop diabetic neuropathy.
- 474 Figure 4:- Nomogram for develop and validate risk prediction model for diabetic
- neuropathy among diabetes mellitus patients, northwest Ethiopia, 2005-2021.
- 476 The performance of developed nomogram in predicting diabetic neuropathy was AUC= 73.2
- 477 %(95% CI; 69.0%, 77.3%), had good level of accuracy (Figure-5, A) and calibration test (p-
- value 0.502), the model was well calibrated model, indicates the observed probability was
- agreement with expected probability (Figure-5, B).
- 480 Figure 5: Performance of model using nomogram A) AUC B) Calibration plot,
- 481 prediction for the risk of diabetic neuropathy among DM patients North West Ethiopia
- 482 **2005-2021.**

Prediction model development using machine learning by classification and

484 regression tree

483

491

492

493

507

508

509

485 Besides the model developed by nomogram, it also presented by machine learning algorism 486 with classification and regression tree analysis suitable when continuous and categorical 487 variables used that predict diabetic neuropathy. The prediction rate (accuracy) for diabetic 488 neuropathy in classification and regression tree was 78.7% (Table-6).

489 Table 6:- Prediction rate of diabetic neuropathy among DM patients using machine 490 learning by CRT decision tree in North West Ethiopia, 2005-2021

	Cla	ssification	
Observed	Predi		
	No	Yes	Percent Correct
No	636	0	100.0%
Yes	172	0	0.0%
Overall Percentage	100.0%	0.0%	78.7%

494 From eight significant variables used for nomogram development, the classification and 495 regression tree (CRT) select five most potent predictors includes other comorbidities, glycemic 496 control, physical activity, White blood cells and red blood cells count. Presence of 497 comorbidities was the most important node that predicts diabetic neuropathy, followed by 498 glycemic control and physical activity; low RBC and high WBC count. For instance, from 172 499 having diabetic neuropathy cases, 59(43.1%) had presence other comorbidities and no doing 500 physical activity were develop diabetic neuropathy. In classification and regression tree there 501 were four depths, six terminal nodes used for decisions (Figure-6).

502 Figure 6:-Classification and regression decision tree for prediction of diabetic neuropathy 503 among diabetes mellitus patients North West Ethiopia 2005-2021

The performance of the classification and regression decision tree was good accuracy with AUC=70.2 %(95 % CI; 65.8%, 74.6%) (Figure:-7, A) and well calibrated model (p-value - 0.412) (Figure:-7, B), which means the predicting and observed probability was the same

Figure 7:-The Performance of the model using decision tree A) AUC B) calibration plot to prediction of the risk for diabetic neuropathy among DM patients North West Ethiopia 2022.

Internal validation

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

- In order to checking over fitting and bias of the developed model using nomogram and decision tree, bootstrapping technique were used for internal validation. The area under ROC curve was assessed based on the bootstrap dataset coefficients. The developed nomogram was internally validated had AUC; 71.7(95% CI; 67.3 %, 76.0%) (Figure-8, A) and well calibration model (p-value- 0.945)(Figure-8, B) After internal validation the discriminating performance of nomogram was comparable with less optimism coefficients found to be 0.015, which indicates less likely over fitting model and bias. The average calculated value of optimism to the performance model was 0.0075. Figure 8: The performance of the model using nomogram after bootstrapping A) Area under the curve (AUC) B) calibration plot, for the probability of the risk of diabetic neuropathy among DM patients North West Ethiopia, 2005-2021. The performance of the classification and regression decision tree after bootstrapping was the same as the developed CRT decision tree ,good accuracy with AUC=70.2 %(95 % CI; 65.8%, 74.6%) (Figure:-9 A) and well calibrated model (p-value:-0.389) (Figure:-9 B). The optimism coefficient was 0.000. Figure 9:-The performance of the model using classification and regression decision tree after bootstrapping A) AUC B) Calibration plot to predict diabetic neuropathy among DM patients northwest Ethiopia 2022. In both nomogram and classification and regression tree (CRT) the discrimination and calibration performance power were comparable, good accuracy so that, they were used to predict the risk of diabetic neuropathy among DM patients (Figure-10) Figure 10: Comparison of nomogram and decision tree for prediction of diabetic neuropathy among DM patients North West Ethiopia 2005-2021. Cutoff point for probability of diabetic neuropathy by nomogram and **CRT** Using the nomogram, optimal cutoff point for predicted probability for risk of diabetic
- neuropathy by using Youden's index(J) was 0.2447 and the sensitivity, specificity, positive predictive value and negative predictive value was 65.2%(95% CI; 58;0%, 72.2%),

539 71.7%(95% CI; 68.0%, 75.2%), 38.4%(95% CI; 32.7 %, 44.2%), 88.4% (95% CI; (85.3%, 91.0%) respectively.(Table-7)

Table 7:-Sensitivity, Specificity, PPV, NPV, LR+, LR- and Accuracy of the nomogram at different cut-off points for prediction of diabetic neuropathy among DM patients

North West Ethiopia 2005-2021.

Cutoff	Sensitivity	Specificity	Accuracy	PPV	NPV	LR+	LR_
>=0.1	72.1%	63.5	65.4%	35.3%	90.4%	1.9	0.4
>=0.2	70.4%	66.4%	67.2%	36.1%	89.2	2.1	0.4
>=0.24	65.2%	71.7%	70.3%	38.4%	88.4	2.3	0.4
>=0.3	54.7%	78.6%	73.5%	41.0%	86.5%	2.5	0.5
>=0.4	34.3 %	88.4%	77.0%	44.4%	83.3%	2.9	0.7

In classification and regression tree(CRT) using optimal cutoff point for predicting the probability risk of diabetic neuropathy by using Youden's index was 0.1847 and the sensitivity, specificity, positive predictive value and negative predictive value was 72.09 (95% CI; 64.8%, 78.6%), 57.7%(95% CI; 53.8%, 61.6%), 31.5%(95% CI; 27.0 %, 36.4%), 88.4% (95% CI; (84.9%, 91.3%) respectively.

Risk classification for diabetic neuropathy using nomogram

For easily practical utility we developed nomogram by using regression coefficients in the final reduced model. The proportion of diabetes mellitus patients to risk of diabetic neuropathy at low risk was 516(63.8%), intermediate risk 282(34.90%) and high risk group 10(1.24%). When the risk classified as two categories the proportions of DM patients for risk of diabetic neuropathy at low risk was 516(63.86%) and high risk 292(36.14%). (Table-8)

Table 8: Risk classification for predicting diabetic neuropathy among DM patients using nomogram, Northwest Ethiopia, 2005-2021 (n=808)

Risk categories'	Total number of DM patients	Incidence of diabetic neuropathy
Low risk(<0.2)	516(63.86%)	60(7.4%)
Intermediate risk(0.2-0.6)	282(34.90)	107(13.3%)
High risk(>0.6)	10(1.24%)	5 (0.6%)
Total	808(100%)	172(21.3%)

- In classification and regression tree (CRT), the proportion diabetes mellitus patients to the
- risk of diabetic neuropathy at low risk was 150(18.56%), intermediate risk 636(78.72) and
- 561 high risk 22(2.72%).

570

574

585

Decision Curve analysis

- Besides model performance assessed by AUC, calibration plot, sensitivity, specificity and
- accuracy, clinical and public health utility of the model was also assessed by decision curve
- analysis. The developed model using nomogram and classification and regression tree (thick
- red line} had highest net benefit from threshold probabilities greater than 0.1(10%) compared
- treatments none (thick black line), had high cost benefit ratio. The model has no or similar
- net benefit to treatment all (thin black line) regardless of their risk across thresholds below
- 569 0.1 (10%).(Figure-11, A, B)
- Figure 11:-Decision curve plot A) Nomogram B) Decision tree , showing the net benefit
- of the developed model for carrying out a certain intervention measure in DM patients
- at risk of diabetic neuropathy Northwest Ethiopia, 2005-2021

Mobile-based application of nomogram

- To make the nomogram accessible to physicians and patients, mobile based application tool
- were developed for predicting the risk of diabetic neuropathy among diabetes mellitus
- patients by using "sublime text "application with java script. Where physicians' or diabetes
- 578 mellitus patients enter their selected clinical and laboratory data to the developed mobile
- based tool, then the tool was giving alert as cutoff value 26 get from nomogram, weather they
- are at low risk (<26) or high risk (>=26) of diabetic neuropathy by calculating cumulating
- score in order to keep or improve their health condition. In Figure:-15 when we enter data to
- the tool had score 21.2
- Figure 12:-Mobile based application outputs for predicting risk of diabetic neuropathy
- among DM patients Northwest Ethiopia 2005-2021.

Discussion

- This risk prediction model used a multicenter retrospective follow up study to develop a
- practical tool for prediction of diabetic neuropathy among both type-1 and type-2 DM
- patients. Our study established a diabetic neuropathy risk prediction model using combined

- set predictors to be used in the primary care settings, by developing nomogram and decision
- tree, aid in public health and clinical decision making for clinicians and to patients.
- 591 There were challenges to diagnose diabetic neuropathy, which needs electro physical and
- autonomic tests by mono filaments, is not available in low level health care system (60, 61)
- Hence, predicting the risk of diabetic neuropathy in diabetes mellitus patients using easily
- measurable predictors were essential to take appropriate measures accordingly.
- The study finding showed that the incidence proportion of diabetic neuropathy was 21.29
- 596 %(95%CI; 18.59, 24.25), which is consistent with SRMA study in North Africa, 21.9% (18),
- 597 Ethiopia, 22% (50), Qatar 23.0%(62) but lower than Tikur Anbesa and St. Paulous
- 598 hospital,48.2% (20), SRMA in Africa 46% (15), Srilanka 28.8% (14).
- These disparities might be number of participates involved with sample size difference, in
- case small sample size in this study(63), difference way of life style (64) and different level of
- 601 health care system used for diagnosis. For instance, monofilament examination was not
- performed in our study area, results asymptomatic patients may not detect.
- The model was developed by reducing twenty-two candidate predictors to thirteen potential
- predictors, which were passed to multivariable analysis. The model comprised eight variables
- 605 identified as independent predictors of diabetic neuropath including glycemic control (FBG),
- other comorbidities, alcohol drinking, Hypertension, type of treatment for DM, physical
- activity, WBC and RBC count. This result is supported by previous studies conducted (65),
- 608 (66), (37), (42), (47), (67).
- The prediction model developed from eight predictors and nomogram was developed found
- to have discrimination accuracy of AUC; 73.2% This result showed that a good accuracy
- discrimination power according to diagnostic accuracy classification criteria(68). The model
- calibration assessed by calibration plot and Hosmer and Lemeshow test had p-value; 0.502,
- which had good agreement between observed and expected probability.
- The predictive role of each predictors was assessed for the identification of individuals at
- greater risk of diabetic neuropathy and its capacity of score from nomogram for glycemic
- control (poor), physical activity (no), other comorbidities (yes), alcohol drinking (yes), use
- combined insulin and oral drugs, hypertension (yes), WBC (high) and RBC (low) was 2.6,
- 618 10, 7, 6.4, 4, 2.6, 7.8 and 6.8 respectively.
- The model was internally validated using the bootstrapping method of 1000 repetitions with
- 620 replacement. The discriminating performance of the model after internal validation had also
- good discrimination power of AUC ;71.7% with well calibrated model (p value = 0.945). The

622 optimism coefficient was found to be 0.015(1.5%), ensures that the model is less likely over fitting and less sample dependent, can easily and accurately individualized prediction of the 623 risk of diabetic neuropathy. 624 The performance of our model was found to be consistent with other prediction models 625 626 developed to predict diabetic neuropathy among DM patients, using hypertension, age, heart 627 rate and BMI as predictors, AUC; 71% in china(69) using hypertension, comorbidities, gender, age, obesity, abnormal triglycerides as predictors, AUC; 75% in china (70), but better 628 than a study using glomerular filtration rate, glibenclamide and creatinine as predictors 629 630 AUC=66.05% in Mexico (71), using age, FBG, PBG, HbA1c, LDL, HDL and BMI as predictors AUC; 55.6% in china(72), using FBG, BMI, age as predictors AUC; 63.50 in 631 Korea (73). This might be due to difference in study participants involved through socio-632 633 demographic characteristics, difference number of predictors used in the model development (74). The model calibration based on Hosmer and Lemshow test P-value; 0.945, is consistent 634 another study 0.52 in china (72), indicates well calibrated model. 635 However, the discriminative performance of the model was lower than a study done in Italy 636 using type of DM, smoke, BMI and HbA1c as predictors AUC: 76.9%(75) and AUC: 85.9% 637 in china(40). This might sample size variation, use variety of validation techniques, the lower 638 number of predictors incorporated in case of our study compared to others, use machine 639 learning algorism, to select the most potent predictors increases the power of the study (74). 640 In our nomogram prediction score, using 0.24 as cutoff point has an acceptable level of the 641 sensitivity; specificity was 65.2%, 71.2%, respectively. Using 0.18 as cut off point in 642 classification and regression tree (CRT) had also acceptable level of sensitivity; specificity 643 was 72.09% and 57.7% respectively. Thus it was better to identify diabetic neuropathy cases 644 and possible to shift the cutoff point to increase either of the accuracy measures depending 645 on the aim of program and availability of resources. 646 The benefit that the developed nomogram and decision tree would add to clinical practice 647 was also presented in the form of a decision curve analysis. In our study the decision curve 648 analysis showed that there was high net benefit than using treat all or treat none strategies 649 when the threshold probability of the patient greater than 0.1(10%) in both nomogram and 650 classification and regression tree(CRT). However, the model is not useful for threshold 651 probabilities below 10%. Thus, threshold probabilities are the most important components of 652 the decision curve analysis depending on which a clinician can decide on whether to use the 653

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

673

674

675

676

677

678

679

680

681

682

683

684

685

model or not when there is a need to carry out an intervention for patients at risk of diabetic neuropathy. Although the autonomic tests by monofilament examination and nerve conduction studies gives better diagnosis of diabetic neuropathy (76). However, prediction of diabetic neuropathy among type-1 and type-2 DM patients using clinical and behavioral characteristics of alone enabled to identify low and high risk diabetes mellitus patients. This prediction model is not a replacement of electro physical diagnosis and monofilament examination of diabetes mellitus patients to diagnose diabetic neuropathy (77); however, it will be as screening tool in resource poor settings for further diagnostic workup and management options. Besides the nomogram and decision tree is easier to use in routine clinical and public health practice than regression models and has comparable discrimination and calibration. This study has following strengths. Firstly, it was conducted multicenter study and mobile based application toll was developed for easily applicability. Secondly, the model was internally validated using bootstrapping technique, resulted small optimism coefficient, indicating our model is less likely over fitted model, can easily predict the risk of diabetic neuropathy. Thirdly, this prediction model is constructed from easily obtainable clinical and behavioral predictors that make it applicable in primary care settings. Finally the model was also developed by classification and regression tree analysis to show the interaction effect of each predictor to the risk of diabetic neuropathy. However, the findings from this study should be interpreted with the perspective of the following limitations. Even if multicenter studies, the model did not validate in separate datasets so that it needs external validation before using it in another context. In addition most diabetic neuropathy patient was asymptomatic may missed cases, who had no sign and symptoms. The study had many missing predictors due to retrospective study design. Generally the model will provide its maximum benefit in clinical practice provided that all the required predictor information is collected and developing mobile based application makes it the nomogram easily applicable for clinicians and to patients.

Conclusion and recommendation

The model was developed from precisely measured, clinical and behavioral predictors found in primary health care setting includes glycemic control(FBG), hypertension, physical activity, other comorbidities, alcohol drinking, type of treatment for DM, WBC and RBC

686 count. The model was presented by nomogram and decision tree with having good discriminating performance power and well calibrated. It was internally validated by 687 bootstrapping techniques with small optimum coefficients, less likely of over fitting of the 688 model. The nomogram was better than decision tree, helps us to do a risk stratification of 689 690 diabetes mellitus patients and to identify those at higher risk of having diabetic neuropathy. 691 Subsequently, high-risk groups can be linked to a center, which is equipped with electro physical diagnosis and monofilament examination centers for further assessment and better 692 693 management. The nomogram and decision tree had added net benefit in clinical practice as it 694 was assured by decision curve analysis across different threshold probabilities. To make easily accessible and applicable of nomogram for clinicians and to patients, mobile based 695 application tool (off line) were developed, that works for both type-1 and Type-2 DM 696 697 patients to calculate their risk in order to take appropriate intervention measures timely. Based on study findings, we recommend that for health professionals, who are providing 698 health care services at diabetes mellitus chronic follow up clinic, use the nomogram 699 developed by mobile based application tool to identify high risk of diabetic neuropathy 700 patients for early management and treatment. Additionally Patients use this developed mobile 701 based application tool for their informed choice of treatment by calculating their 702 703 individualized risk either to keep or improve their health condition. Finally for future researchers improve the model by adding additional predictors like HbA1c, family history of 704 DM and smoking through prospective study design and using monofilament examination by 705 detect enough number of events. Besides, validate externally by using independent sample 706 707 datasets to be applicable in all health institution.

Abbreviations

708

- 709 AUC; Area under the Curve BMI; Body Mass Index CI; Confidence Interval
- 710 CRT; Classification and Regression Tree DBP; Diastolic Blood Pressure DCA; Decision
- 711 Curve Analysis DM; Diabetes Mellitus DPN; Diabetic Peripheral Neuropathy
- FBG; Fasting Blood Glucose HDL; High Density Lip-Protein HbA1c; Glycated Hemoglobin
- A1 c ICT; Information Communication Technology IDF; International Diabetes Federation
- 714 IOR; Inter Ouartile Range LASSO; Least Absolute Shrinkage and Selection Operator LDL;
- Low Density Lip-Protein LR+; Log Likelihood Ratio Positive LR; Log Likelihood Ratio
- Negative MNSI; Michigan Neuropathy Screening Instrument NPV; Negative Predictive
- 717 Value PBG; Post Bradial Glucose PPV; Positive Predictive Value RBC; Red Blood Cells
- 718 ROC; Receiver Operating Characteristics SBP; Systolic Blood Pressure SRMA; Systematic

- 719 Review and Meta-Analysis T1DM; Type-1 Diabetes Mellitus T2DM; Type-2 Diabetes
- 720 Mellitus TC; Total Cholesterol TG; Total Triglyceride UOG; University of Gondar WBC;
- 721 White Blood Cells
- 722 **Declarations**

723 Ethics approval and consent to participate

- 724 The study use ethical clearance from university of Gondar for the collection of information
- 725 from subjects (supplementary file-S3)

726 Availability of data and materials

Data is available on the manuscript and as supplementary files.

Competing Interests

729 The authors declare that they have no conflict of interest.

730 Funding

728

- Funding was obtained from Mizan Aman college of health science, Mizan-Aman, Ethiopia
- 732 (25,000 Ethiopian Birr)

733 Author's Contributions

- 734 Conceptualization: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
- 735 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
- 736 Gebi
- 737 Data curation: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
- 738 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie ,Tsion Mulat Tebeje, Nebiyu Bekele
- 739 Gebi
- 740 Formal analysis: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke
- 741 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele
- 742 Gebi

743 **Investigation:** Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem, 744 Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi 745 Methodology: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele 746 747 Gebi Software; Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem, 748 Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi 749 750 Validation: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi 751 Visualization: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw Zeleke 752 753 Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi 754 Writing original draft: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, Adugnaw 755 756 Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi 757 Writing – review & editing: Negalgn Byadgie Gelaw, Achenef Asmamaw Muche, 758 759 Adugnaw Zeleke Alem, Yazachew Moges Chekol, Tigabu Kidie Tesfie, Tsion Mulat Tebeje, Nebiyu Bekele Gebi 760 761 All authors read and approved the final manuscript. Acknowledgments 762 763 We greatly acknowledge Mizan Aman College of health sciences for sponsorship and 764 university of Gondar 765 Supplementary file

- 766 S1:- Missing variables and its percentage for prediction of diabetic neuropathy among
- 767 DM patients Northwest Ethiopia, 2005-2021.
- 768 S2: Predictive performance of for individual and combined predictors by AUC value
- for prediction of diabetic neuropathy among DM patients North West Ethiopia 2005-
- 770 **2021.**

773

771 S3:-Ethical Clearance letter obtained from university of Gondar

References

- 1. Czech MP. Insulin action and resistance in obesity and type 2 diabetes. Nature medicine. 2017;23(7):804-14.
- Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nature Reviews Endocrinology. 2018;14(2):88-98.
- 3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021
- and projections for 2045. Diabetes research and clinical practice. 2022;183:109119.
- 781 4. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for
- 783 2045. Diabetes Res Clin Pract. 2018;138:271-81.
- Tuomi T, Santoro N, Caprio S, Cai M, Weng J, Groop L. The many faces of diabetes:
- a disease with increasing heterogeneity. Lancet (London, England). 2014;383(9922):1084-94.
- 787 6. Cho N, Shaw J, Karuranga S, Huang Y, da Rocha Fernandes J, Ohlrogge A, et al. IDF
- Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.
- 789 Diabetes research and clinical practice. 2018;138:271-81.
- 790 7. Association AD. Standards of medical care in diabetes—2016 abridged for primary
- 791 care providers. Clinical diabetes: a publication of the American Diabetes Association. 792 2016;34(1):3.
- 8. Edwards JL, Vincent AM, Cheng HT, Feldman EL. Diabetic neuropathy: mechanisms to management. Pharmacology & therapeutics. 2008;120(1):1-34.
- 795 9. Rojas-Carranza CA, Bustos-Cruz RH, Pino-Pinzon CJ, Ariza-Marquez YV, Gomez-
- Pharmacogenomics. Current pharmaceutical design. 2018;24(15):1695-710.
- 798 10. Said G. Diabetic neuropathy. Handbook of clinical neurology. 2013;115:579-89.
- 799 11. Li L, Chen J, Wang J, Cai D. Prevalence and risk factors of diabetic peripheral
- neuropathy in type 2 diabetes mellitus patients with overweight/obese in Guangdong province, China. Primary care diabetes. 2015;9(3):191-5.
- province, China. Primary care diabetes. 2013,9(3).191-3.
- 802 12. Pfannkuche A, Alhajjar A, Ming A, Walter I, Piehler C, Mertens PR. Prevalence and
- risk factors of diabetic peripheral neuropathy in a diabetics cohort: Register initiative "diabetes and nerves". Endocrine and Metabolic Science. 2020;1(1):100053.
- 805 13. Bansal D, Gudala K, Muthyala H, Esam HP, Nayakallu R, Bhansali A. Prevalence
- and risk factors of development of peripheral diabetic neuropathy in type 2 diabetes mellitus in a tertiary care setting. Journal of diabetes investigation. 2014;5(6):714-21.
- 808 14. Katulanda P, Ranasinghe P, Jayawardena R, Constantine GR, Sheriff MHR,
- Matthews DR. The prevalence, patterns and predictors of diabetic peripheral neuropathy in a
- developing country. Diabetology & Metabolic Syndrome. 2012;4(1):21.

- 811 15. Shiferaw WS, Akalu TY, Work Y, Aynalem YA. Prevalence of diabetic peripheral
- neuropathy in Africa: a systematic review and meta-analysis. BMC endocrine disorders.
- 813 2020;20(1):49.
- 16. Jacovides A, Bogoshi M, Distiller LA, Mahgoub EY, Omar MK, Tarek IA, et al. An
- epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among
- adults with diabetes attending private and institutional outpatient clinics in South Africa.
- Journal of International Medical Research. 2014;42(4):1018-28.
- 818 17. Seid MA, Akalu Y, Gela YY, Belsti Y, Diress M, Fekadu SA, et al. Microvascular
- complications and its predictors among type 2 diabetes mellitus patients at Dessie town
- hospitals, Ethiopia. Diabetology & Metabolic Syndrome. 2021;13(1):1-8.
- 821 18. Bos M, Agyemang C. Prevalence and complications of diabetes mellitus in Northern
- Africa, a systematic review. BMC public health. 2013;13(1):1-7.
- 19. Jember G, Melsew YA, Fisseha B, Sany K, Gelaw AY, Janakiraman B. Peripheral
- 824 Sensory Neuropathy and associated factors among adult diabetes mellitus patients in Bahr
- Dar, Ethiopia. Journal of diabetes and metabolic disorders. 2017;16:16.
- 326 20. Jarso G, Ahmed A, Feleke Y. The prevalence, clinical features and management of
- periphral neuropathy among diabetic patients in Tikur Anbessa and St. Paul's Specialized
- University Hospitals, Addis Ababa, Ethiopia. Ethiopian medical journal. 2011;49(4):299-
- 829 311.
- 830 21. Selvarajah D, Kar D, Khunti K, Davies M, Scott A, Walker J. Diabetic peripheral
- 831 neuropathy: Advances in diagnosis and strategies for screening and early intervention. Lancet
- 832 Diabetes Endocrinol [Internet]. 2019; 7 (12): 938–48.
- 833 22. (FMOH) FMoH. National Strategic Action Plan (Nsap) for Prevention & Control of
- Non-Communicable Diseases in Ethiopia. 2016.
- 835 23. Smith BH, Hébert HL, Veluchamy A. Neuropathic pain in the community:
- prevalence, impact, and risk factors. Pain. 2020;161 Suppl 1:S127-s37.
- 837 24. Marshall A, Alam U, Themistocleous A, Calcutt N, Marshall A. Novel and Emerging
- 838 Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy.
- 839 Clinical therapeutics. 2021;43(9):1441-56.
- 840 25. Kent P, Cancelliere C, Boyle E, Cassidy JD, Kongsted A. A conceptual framework
- for prognostic research. BMC Med Res Methodol. 2020;20(1):172.
- 842 26. Ambizas EM, Maniara B. Diabetic Peripheral Neuropathy How Can We Help Our
- Patients?: JOBSON PUBLISHING LLC 100 AVE OF THE AMERICAS, NEW YORK, NY
- 844 10013-1678 USA; 2016. p. 8-14.
- Yang Z, Zhang Y, Chen R, Huang Y, Ji L, Sun F, et al. Simple tests to screen for
- 846 diabetic peripheral neuropathy: Cochrane Database Syst Rev. 2018 Jul
- 30;2018(7):CD010975. doi: 10.1002/14651858.CD010975.pub2. eCollection 2018 Jul.
- 28. Lu Y, Xing P, Cai X, Luo D, Li R, Lloyd C, et al. Prevalence and Risk Factors for
- Diabetic Peripheral Neuropathy in Type 2 Diabetic Patients From 14 Countries: Estimates of
- the INTERPRET-DD Study. Frontiers in Public Health. 2020;8.
- 851 29. Moons KG, Royston P, Vergouwe Y, Grobbee DE, Altman DG. Prognosis and
- prognostic research: what, why, and how? Bmj. 2009;338.
- 853 30. Chicharro-Luna E, Pomares-Gómez FJ, Ortega-Ávila AB, Coheña-Jiménez M, Gijon-
- Nogueron G. Variability in the clinical diagnosis of diabetic peripheral neuropathy. Primary
- 855 care diabetes. 2020;14(1):53-60.
- 856 31. Coppini DV. Diabetic neuropathy: are we still barking up the wrong tree and is
- change finally in sight? Diabetologia. 2020;63(9):1949-50.
- 858 32. Mendoza-Romo MA, Ramírez-Arriola MC, Velasco-Chávez JF, Nieva-de Jesús RN,
- 859 Rodríguez-Pérez CV, Valdez-Jiménez LA. [Sensitivity and specificity of a utility model of

- the detection of diabetic neuropathy]. Revista medica del Instituto Mexicano del Seguro
- 861 Social. 2013;51(1):34-41.
- 33. Jambart S, Ammache Z, Haddad F, Younes A, Hassoun A, Abdalla K, et al.
- Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in
- the Middle East region. The Journal of international medical research. 2011;39(2):366-77.
- 865 34. Chicharro-Luna E, Pomares-Gómez FJ. Predictive model to identify the risk of losing
- protective sensibility of the foot in patients with diabetes mellitus. 2020;17(1):220-7.
- 867 35. Papanas N, Ziegler D. Polyneuropathy in impaired glucose tolerance: is postprandial
- hyperglycemia the main culprit? A mini-review. Gerontology. 2013;59(3):193-8.
- 869 36. Xiao M-X, Lu C-H, Ta N, Wei H-C, Haryadi B, Wu H-T. Machine learning
- prediction of future peripheral neuropathy in type 2 diabetics with percussion entropy and
- body mass indices. Biocybernetics and Biomedical Engineering. 2021;41(3):1140-9.
- 872 37. Said G. Diabetic neuropathy. Handbook of clinical neurology. 2013;115:579-89.
- 873 38. Wolde HF, Atsedeweyen A, Jember A, Awoke T, Mequanent M, Tsegaye AT, et al.
- Predictors of vascular complications among type 2 diabetes mellitus patients at University of
- 875 Gondar Referral Hospital: a retrospective follow-up study. BMC Endocrine Disorders.
- 876 2018;18(1):52.
- 39. Gebabo TF, Zewdie TH, Shagaro SS, Haile F. Determinants of peripheral neuropathy
- among diabetic patients under follow-up in chronic care clinics of public hospitals at Gamo
- and Gofa zones, southern Ethiopia. PloS one. 2021;16(2):e0246722.
- 880 40. Fan Y, Long E, Cai L, Cao Q, Wu X, Tong R. Machine Learning Approaches to
- Predict Risks of Diabetic Complications and Poor Glycemic Control in Nonadherent Type 2
- Diabetes. Frontiers in pharmacology. 2021;12:665951.
- 883 41. Wang N, Guo C, Han P, Li T. Glycated albumin indicates peripheral diabetic
- neuropathy. Acta diabetologica. 2016;53(6):973-9.
- 885 42. Yamazaki D, Hitomi H, Nishiyama A. Hypertension with diabetes mellitus
- complications. Hypertension Research. 2018;41(3):147-56.
- 887 43. Cai Z, Yang Y, Zhang J. A systematic review and meta-analysis of the serum lipid
- profile in prediction of diabetic neuropathy. Sci Rep. 2021;11(1):499.
- 889 44. Tabatabaei-Malazy O, Mohajeri-Tehrani M, Madani S, Heshmat R, Larijani B. The
- 890 prevalence of diabetic peripheral neuropathy and related factors. Iranian journal of public
- 891 health. 2011;40(3):55.
- 892 45. Wu B, Niu Z, Hu F. Study on Risk Factors of Peripheral Neuropathy in Type 2
- Diabetes Mellitus and Establishment of Prediction Model. Diabetes Metab J. 2021;45(4):526-
- 894 38.
- 895 46. Abougalambou SS, Abougalambou AS. Explorative study on diabetes neuropathy
- among type II diabetic patients in Universiti Sains Malaysia Hospital. Diabetes & metabolic
- 897 syndrome. 2012;6(3):167-72.
- 898 47. Nalluri L, Mannam M, Vemireddy N, Akula N, Pothuraju M, Pinnika D, et al.
- Assessment of drug utilization pattern and risk factors for the development of diabetic
- 900 neuropathy among type 2 diabetic patients in a south Indian hospital: A cross-sectional
- observational study. Journal of Applied Pharmaceutical Science. 2019;9(12):069-77.
- 902 48. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et
- al. Diabetic neuropathy. Nature reviews Disease primers. 2019;5(1):1-18.
- 904 49. Steverberg EW, Moons KG, van der Windt DA, Hayden JA, Perel P, Schroter S, et al.
- Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS medicine.
- 906 2013;10(2):e1001381.
- 50. Tadesse DB, Gebrewahd GT, Hailay A, Aberhe W, Mebrahtom G, Zereabruk K, et al.
- 908 Diabetic peripheral neuropathy in Ethiopia: a systematic review and meta-analysis. Journal of
- 909 Diabetes Research. 2021;2021.

- 910 51. Gill G, Mbanya J-C, Ramaiya K, Tesfaye S. A sub-Saharan African perspective of
- 911 diabetes. Diabetologia. 2009;52(1):8-16.
- 912 52. Assessment G. 6. Glycemic Targets: Standards of Medical Care in Diabetes—2022.
- 913 Diabetes Care. 2022;45:S83.
- 914 53. Carroll MD, Kit BK, Lacher DA. Total and high-density lipoprotein cholesterol in
- adults; national health and nutrition examination survey, 2009-2010. 2012.
- 916 54. Bain BJ. Blood cells: a practical guide: John Wiley & Sons; 2021.
- 917 55. Kent S, Fusco F, Gray A, Jebb SA, Cairns BJ, Mihaylova B. Body mass index and
- 918 healthcare costs: a systematic literature review of individual participant data studies. Obesity
- 919 Reviews. 2017;18(8):869-79.
- 920 56. Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more
- 921 than meets the eye. The Lancet Oncology. 2015;16(4):e173-80.
- 922 57. Ge X, Pan SM, Zeng F, Tang ZH, Wang YW. A simple Chinese risk score model for
- 923 screening cardiovascular autonomic neuropathy. PloS one. 2014;9(3):e89623.
- 924 58. Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a
- 925 multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD
- 926 statement. Journal of British Surgery. 2015;102(3):148-58.
- 927 59. Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to
- 928 interpreting decision curve analysis. Diagnostic and prognostic research. 2019;3:18.
- 929 60. Jensen TS, Karlsson P, Gylfadottir SS, Andersen ST, Bennett DL, Tankisi H, et al.
- 930 Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for
- 931 future management. Brain. 2021;144(6):1632-45.
- 932 61. Malik RA, Andag-Silva A, Dejthevaporn C, Hakim M, Koh JS, Pinzon R, et al.
- 933 Diagnosing peripheral neuropathy in South-East Asia: a focus on diabetic neuropathy.
- 934 Journal of Diabetes Investigation. 2020;11(5):1097-103.
- 935 62. Ponirakis G, Elhadd T, Chinnaiyan S, Dabbous Z, Siddiqui M, Al-muhannadi H, et al.
- 936 Prevalence and management of diabetic neuropathy in secondary care in Oatar.
- Diabetes/Metabolism Research and Reviews. 2020;36(4):e3286.
- 938 63. Heckmann T, Gegg K, Gegg A, Becht M. Sample size matters: investigating the
- 939 effect of sample size on a logistic regression susceptibility model for debris flows. Natural
- 940 Hazards and Earth System Sciences. 2014;14(2):259-78.
- 941 64. Bando H. Significant Neurological Study for Lifestyle Related Diseases Worldwide
- 942 From Now. Journal of Health Care and Research. 2020;1(2):50-4.
- 943 65. Fasil A, Biadgo B, Abebe M. Glycemic control and diabetes complications among
- 944 diabetes mellitus patients attending at University of Gondar Hospital, Northwest Ethiopia.
- Diabetes, metabolic syndrome and obesity: targets and therapy. 2019;12:75.
- 946 66. YimamAhmed M, Ejigu SH, Zeleke AZ, Hassen MY. Glycemic control, diabetes
- 947 complications and their determinants among ambulatory diabetes mellitus patients in
- 948 southwest ethiopia: A prospective cross-sectional study. Diabetes, Metabolic Syndrome and
- 949 Obesity: Targets and Therapy. 2020;13:1089.
- 950 67. Huang L, Shen X, Huang L, Yan S, Wu P. Identification of independent risk factors
- 951 for diabetic neuropathy progression in patients with type 2 diabetes mellitus. Journal of
- 952 International Medical Research. 2021;49(9):03000605211044366.
- 953 68. Simundić A-M. Measures of diagnostic accuracy: basic definitions. Ejifcc.
- 954 2009;19(4):203.
- 955 69. Ge X, Pan S-M, Zeng F, Tang Z-H, Wang Y-W. A simple Chinese risk score model
- 956 for screening cardiovascular autonomic neuropathy. PloS one. 2014;9(3):e89623.
- 957 70. Liao L-N, Li T-C, Li C-I, Liu C-S, Lin W-Y, Lin C-H, et al. Genetic risk score for
- 958 risk prediction of diabetic nephropathy in Han Chinese type 2 diabetes patients. Scientific
- 959 reports. 2019;9(1):1-9.

- 960 71. Maeda-Gutiérrez V, Galván-Tejada CE, Cruz M, Valladares-Salgado A, Galván-
- Tejada JI, Gamboa-Rosales H, et al., editors. Distal symmetric polyneuropathy identification
- in type 2 diabetes subjects: A random forest approach. Healthcare; 2021: MDPI.
- 963 72. Wu B, Niu Z, Hu F. Study on Risk Factors of Peripheral Neuropathy in Type 2
- Diabetes Mellitus and Establishment of Prediction Model. Diabetes & metabolism journal.
- 965 2021;45(4):526-38.
- 966 73. Shin DY, Lee B, Yoo WS, Park JW, Hyun JK. Prediction of Diabetic Sensorimotor
- 967 Polyneuropathy Using Machine Learning Techniques. Journal of Clinical Medicine.
- 968 2021;10(19):4576.
- 969 74. Muschelli J. ROC and AUC with a binary predictor: a potentially misleading metric.
- 970 Journal of classification. 2020;37(3):696-708.
- 971 75. Dagliati A, Marini S, Sacchi L, Cogni G, Teliti M, Tibollo V, et al. Machine learning
- 972 methods to predict diabetes complications. Journal of diabetes science and technology.
- 973 2018;12(2):295-302.
- 974 76. Marshall A, Alam U, Themistocleous A, Calcutt N, Marshall A. Novel and emerging
- 975 electrophysiological biomarkers of diabetic neuropathy and painful diabetic neuropathy.
- 976 Clinical therapeutics. 2021;43(9):1441-56.
- 977 77. Petropoulos IN, Ponirakis G, Khan A, Almuhannadi H, Gad H, Malik RA.
- 978 Diagnosing diabetic neuropathy: something old, something new. Diabetes & metabolism
- 979 journal. 2018;42(4):255.

981




Figure 1:-Flowchart of participant selection for the development of nomogram for prediction of diabetic neuropathy among DM patients in selected referral hospitals, Amhara regional state, North West Ethiopia, 2005-2021.




Figure 2; Pie chart for the proportion of diabetic neuropathy among diabetes mellitus patients North West, Ethiopia, 2005-2021.




Figure 3: The performance of the model using original beta coefficients A) AUC B) calibration plot, for prediction of diabetic neuropathy among DM patients North West Ethiopia, 2005-2021.




Figure 4:- Nomogram for develop and validate risk prediction model for diabetic neuropathy among diabetes mellitus patients, northwest Ethiopia, 2005-2021.




Figure 5: Performance of model using nomogram A) AUC B) Calibration plot, prediction for the risk of diabetic neuropathy among DM patients North West Ethiopia 2005-2021.




Figure 6:-Classification and regression decision tree for prediction of diabetic neuropathy among diabetes mellitus patients North West Ethiopia 2005-2021




Figure 7:-The Performance of the model using decision tree A) AUC B) calibration plot to prediction of the risk for diabetic neuropathy among DM patients North West Ethiopia 2022.




Figure 8: The performance of the model using nomogram after bootstrapping A) Area under the curve (AUC) B) calibration plot, for the probability of the risk of diabetic neuropathy among DM patients North West Ethiopia, 2005-2021.




Figure 10: Comparison of nomogram and decision tree for prediction of diabetic neuropathy among DM patients North West Ethiopia 2005-2021.




Figure 11:-Decision curve plot A) Nomogram B) Decision tree ,showing the net benefit of the developed model for carrying out a certain intervention measure in DM patients at risk of diabetic neuropathy Northwest Ethiopia, 2005-2021

Diabetic Neuropathy Risk Prediction Calculator




Figure 12:-Mobile based application outputs for predicting risk of diabetic neuropathy among DM patients Northwest Ethiopia 2005-2021.




Figure 9:-The performance of the model using classification and regression decision tree after bootstrapping A) AUC B) Calibration plot to predict diabetic neuropathy among DM patients northwest Ethiopia 2022.